Day One Biopharmaceuticals (DAWN) Stock Overview
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DAWN Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Day One Biopharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.88 |
| 52 Week High | US$13.20 |
| 52 Week Low | US$5.64 |
| Beta | -1.27 |
| 1 Month Change | 16.93% |
| 3 Month Change | 41.26% |
| 1 Year Change | -0.42% |
| 3 Year Change | -38.13% |
| 5 Year Change | n/a |
| Change since IPO | -54.11% |
Recent News & Updates
Recent updates
Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking
Jan 21
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
Dec 19Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish
Dec 18Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Fly 29% But Investors Aren't Buying For Growth
Nov 08Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Held Back By Insufficient Growth Even After Shares Climb 30%
Sep 06We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 18
FDA Approval And Ipsen Licensing Will Expand Pediatric Treatment Options
FDA approval and the launch of OJEMDA boost long-term revenue growth, addressing unmet medical needs and strong market uptake in pediatric glioma.Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer
Feb 03Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Jan 07Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Shareholder Returns
| DAWN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.0% | 1.7% | -1.6% |
| 1Y | -0.4% | 27.6% | 10.6% |
Return vs Industry: DAWN underperformed the US Biotechs industry which returned 27.6% over the past year.
Return vs Market: DAWN underperformed the US Market which returned 10.9% over the past year.
Price Volatility
| DAWN volatility | |
|---|---|
| DAWN Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DAWN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DAWN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 184 | Jeremy Bender | dayonebio.com |
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers.
Day One Biopharmaceuticals, Inc. Fundamentals Summary
| DAWN fundamental statistics | |
|---|---|
| Market cap | US$1.17b |
| Earnings (TTM) | -US$151.76m |
| Revenue (TTM) | US$133.67m |
Is DAWN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DAWN income statement (TTM) | |
|---|---|
| Revenue | US$133.67m |
| Cost of Revenue | US$14.11m |
| Gross Profit | US$119.56m |
| Other Expenses | US$271.32m |
| Earnings | -US$151.76m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 24, 2026
| Earnings per share (EPS) | -1.48 |
| Gross Margin | 89.44% |
| Net Profit Margin | -113.53% |
| Debt/Equity Ratio | 0% |
How did DAWN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/17 12:09 |
| End of Day Share Price | 2026/02/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Day One Biopharmaceuticals, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Naureen Quibria | Capital One Securities, Inc. |
| Andrea Newkirk | Goldman Sachs |